-
公开(公告)号:US20170135954A1
公开(公告)日:2017-05-18
申请号:US15317628
申请日:2015-06-11
Inventor: Andrew Bellinger , Shiyi Zhang , Carlo Giovanni Traverso , Robert S. Langer , Stacy Mo , Jiaqi Lin , Angela DiCiccio , Dean Liang Glettig , Lowell L. Wood, JR. , Philip A. Eckhoff
CPC classification number: A61K9/0065 , A61K9/0053 , A61K9/48 , A61K31/357 , A61K31/65 , A61K31/7048 , A61K47/10 , A61K47/32 , A61K47/34 , A61K47/40 , A61K47/42 , A61K47/58 , A61K47/6901 , A61M31/002 , C08G18/4277 , C08G18/73 , C08G63/08 , C08G83/006 , C08G2230/00 , C08L33/02 , C08L33/08 , C08L33/14 , C08L2203/02 , Y02A50/411
Abstract: Residence devices as well as their related methods of manufacture and use are generally provided. In some embodiments, a residence device includes a plurality of self-assembling structures that assemble in vivo to form an aggregate structure. Each structure of the plurality of structures includes a first side and a first attachment point that attaches to a second attachment point on another structure of the plurality of structures. The aggregate structure may be sized and shaped to maintain an in vivo position relative to an internal orifice of a subject. The attachment between the first and second attachment points may degrade after a period of time.
-
公开(公告)号:US20160317796A1
公开(公告)日:2016-11-03
申请号:US15143230
申请日:2016-04-29
Applicant: Massachusetts Institute of Technology
Inventor: Shiyi Zhang , Yida Zhao , Carlo Giovanni Traverso , Robert S. Langer
CPC classification number: A61M37/00 , A61L27/26 , A61L27/446 , A61L27/50 , A61L31/041 , A61L31/06 , A61L31/128 , A61L31/14 , A61L2400/16 , A61M2205/0266
Abstract: In accordance with the invention, compositions, devices, and related methods have been developed for medical-related and other applications. In some embodiments, the devices and compositions described herein comprise a triggerable shape memory polymer network. In certain embodiments, the polymer network comprises a covalently crosslinked polymeric material and a non-crosslinked polymeric material associated with the crosslinked polymeric material. In some cases, the polymer network has a first configuration (e.g., as polymerized), and a second configuration (e.g., upon heating and deformation), such that the polymer network can be triggered to recover the first configuration upon heating the polymeric material above a softening temperature of the polymeric material. In certain embodiments, the polymer network comprises a plurality of particles capable of increasing the temperature of the polymer network (e.g., above the softening temperature) in the presence of an external stimulus such as induction, radio frequency, or magnetic resonance, such that the polymer network changes configuration. The polymeric material may be molded into any suitable shape.
Abstract translation: 根据本发明,已经开发了用于医疗相关和其它应用的组合物,装置和相关方法。 在一些实施例中,本文所述的装置和组合物包括可触发的形状记忆聚合物网络。 在某些实施方案中,聚合物网络包括共价交联的聚合物材料和与交联的聚合物材料相关的非交联聚合材料。 在一些情况下,聚合物网络具有第一构型(例如,聚合)和第二构型(例如,在加热和变形时),使得聚合物网络可以在加热上述聚合物材料时被触发以恢复第一构型 聚合材料的软化温度。 在某些实施方案中,聚合物网络包括能够在诸如感应,射频或磁共振的外部刺激的存在下能够增加聚合物网络的温度(例如高于软化温度)的多个颗粒,使得 聚合物网络改变配置。 聚合物材料可以模制成任何合适的形状。
-
公开(公告)号:US20240342099A1
公开(公告)日:2024-10-17
申请号:US18681845
申请日:2022-08-04
Applicant: Massachusetts Institute of Technology , The Brigham and Women's Hospital, Inc. , Novo Nordisk A/S
Inventor: Carlo Giovanni Traverso , Declan Gwynne , Jacob Wainer , Graham Arrick , Jesper Windum , Kuldeep Sanger , Adam Bohr , Brian Mouridsen , Nikolaj Eusebius Jakobsen , Morten Revsgaard Frederiksen , Jens Lolle Laursen , Ludwig Erik Aguilar
IPC: A61K9/48
CPC classification number: A61K9/4808
Abstract: An ingestible device may include one or more deployable limbs configured to orient the ingestible device in a desired orientation. The one or more limbs may be attached to body of the device and wrap around the device in an initial configuration (e.g., prior to deployment of the one or more limbs). The one or more limbs may be configured to deploy when exposed to a predetermined condition. Once the predetermined condition is met, the one or more limbs may extend outwards away from the body such that the one or more deployed limbs serve to orient the ingestible device.
-
公开(公告)号:US12097021B2
公开(公告)日:2024-09-24
申请号:US17397785
申请日:2021-08-09
Applicant: Massachusetts Institute of Technology , Novo Nordisk A/S , The Brigham and Women's Hospital, Inc.
Inventor: Graham Arrick , Torben Sebastian Last , Declan Gwynne , Jacob Wainer , Carlo Giovanni Traverso , Drago Sticker , Cody Cleveland , Aghiad Ghazal , Adam Bohr , Jorrit Jeroen Water , Brian Mouridsen , Jacob Pyung Hwa Jepsen , Bozhidar Nikolaev Kozhuharov , Kim Frandsen , Robert Langer , Yi Lu , Niclas Roxhed , Siheng You
CPC classification number: A61B5/073 , A61B5/076 , A61B5/4839
Abstract: A drug delivery device for administration to a subject is provided. In some embodiments, the drug delivery device includes a reservoir containing an active pharmaceutical ingredient and a potential energy source. The drug delivery device also includes a trigger operatively associated with the potential energy source, where the trigger is configured to actuate at a predetermined location within the subject. The drug delivery device also includes a rupturable membrane disposed along a flow path extending between the reservoir and an outlet, where the membrane is configured to rupture when the trigger is actuated. Once the trigger is actuated, the potential energy from the potential energy source may be released to expel the active pharmaceutical ingredient in a jet through the outlet.
-
25.
公开(公告)号:US12031977B2
公开(公告)日:2024-07-09
申请号:US17118267
申请日:2020-12-10
Inventor: Robert S. Langer , Carlo Giovanni Traverso , Yunhua Shi , Vance Soares , Daniel Reker
IPC: G01N33/50
CPC classification number: G01N33/5088 , G01N33/5044
Abstract: Methods and compositions for determining multiplex interactions between drugs and drug transporters using an intestinal tissue explant are provided.
-
公开(公告)号:US20240216469A1
公开(公告)日:2024-07-04
申请号:US18596376
申请日:2024-03-05
Inventor: Carlo Giovanni Traverso , Ameya R. Kirtane , Junwei Li , Thomas Wang , James Byrne , Alexis Jones
IPC: A61K38/17 , A61K31/495 , A61K45/06 , A61L24/04 , A61L24/06 , A61L24/08 , A61L27/16 , A61L27/18 , A61L27/20 , C12N9/08
CPC classification number: A61K38/1787 , A61K31/495 , A61K45/06 , A61L24/046 , A61L24/06 , A61L24/08 , A61L27/16 , A61L27/18 , A61L27/20 , C12N9/0065 , A61L2300/254 , A61L2300/256 , A61L2300/438 , A61L2400/04 , A61L2430/06 , A61L2430/16 , C12Y111/01006
Abstract: The present disclosure provides compositions, methods, and kits that enable the in situ growth of polymers on or within a subject. In some aspects, the tissue-active monomers, including monomers comprising macromolecules, provide a broad set of material choices for synthetic tissue barriers. In additional aspects, the compositions, methods, and kits are useful for treating or preventing a disease or disorder.
-
公开(公告)号:US20240108241A1
公开(公告)日:2024-04-04
申请号:US18541818
申请日:2023-12-15
Applicant: Massachusetts Institute of Technology , The Brigham and Women's Hospital, Inc. , The General Hospital Corporation
Inventor: Robert S. Langer , Carlo Giovanni Traverso , Malvika Verma , Feyisope Eweje , Christoph Winfried Johannes Steiger , Junwei Li , Nhi Phan , Hen-Wei Huang , Jacqueline Chu , John Ashraf Fou Salama
CPC classification number: A61B5/073 , A61B5/4845 , A61B2562/02 , A61B2562/162 , A61B2562/164
Abstract: Drug delivery articles, resident articles, and retrieval systems e.g., for gram-level dosing, are generally provided. In some embodiments, the residence articles are configured for transesophageal administration, transesophageal retrieval, and/or gastric retention to/in a subject. In certain embodiments, the residence article includes dimensions configured for transesophageal administration with a gastric resident system. In some cases, the residence article may be configured to control drug release e.g., with zero-order drug kinetics with no potential for burst release for weeks to months. In some embodiments, the residence articles described herein comprise biocompatible materials and/or are safe for gastric retention. In certain embodiments, the residence article includes dimensions configured for transesophageal retrieval. In some cases, the residence articles described herein may comprise relatively large doses of drug (e.g., greater than or equal to 1 gram).
-
公开(公告)号:US20230398067A1
公开(公告)日:2023-12-14
申请号:US18035969
申请日:2021-11-10
Inventor: Robert S. Langer , Carlo Giovanni Traverso , Adam Wentworth , Xiaoyue Qi
CPC classification number: A61K9/0065 , A61K38/465 , A61K47/24 , A61K38/4826 , A61K38/443 , A61K38/47 , A61K38/28 , C12Y304/21004 , C12Y101/03004 , C12Y302/01108
Abstract: Articles and methods related to the administration of biomolecules to subjects using metal-organic frameworks are generally described. In some embodiments, an article is described, the article comprising a substrate comprising an adhesive layer, a support layer disposed on at least a portion of the substrate, and an active material disposed on and/or in at least a portion of the support layer, wherein the active material comprises a composite comprising a metal-organic framework and a biomolecule. In certain embodiments, a method of treating a subject with a biomolecule is described, the method comprising administering an article to a subject.
-
公开(公告)号:US11701437B2
公开(公告)日:2023-07-18
申请号:US16612648
申请日:2018-05-14
Applicant: President and Fellows of Harvard College , Massachusetts Institute of Technology , The Brigham and Women's Hospital, Inc. , The General Hospital Corporation
Inventor: Denitsa M. Milanova , George M. Church , Noah Davidsohn , Carl Schoellhammer , Robert S. Langer , Anna I. Mandinova , Carlo Giovanni Traverso
CPC classification number: A61K48/0075 , A61K47/6901 , A61N7/00 , C12N15/86 , A61K9/7023 , C12N2750/14143 , C12N2750/14145 , C12N2750/14151 , C12N2810/859
Abstract: A method for the systemic delivery of a polypeptide within a subject is provided by creating genetically modified skin cells via topical introduction of a genetically engineered virus which delivers a nucleic acid encoding a therapeutic polypeptide for expression by the skin cells, wherein the expressed therapeutic polypeptide is secreted by the skin cells and is introduced into the circulatory system of the subject.
-
公开(公告)号:US20230039421A1
公开(公告)日:2023-02-09
申请号:US17836972
申请日:2022-06-09
Inventor: Andrew Bellinger , Shiyi Zhang , Carlo Giovanni Traverso , Robert S. Langer , Stacy Mo , Tyler Grant , Mousa Jafari , Dean Liang Glettig , Angela DiCiccio , Lowell L. Wood, JR. , Philip A. Eckhoff
IPC: A61K9/00 , C08G18/73 , C08G63/08 , C08G18/42 , A61K47/58 , A61K47/69 , A61K9/48 , A61K31/357 , A61K31/65 , A61K31/7048 , C08G83/00 , A61K47/32 , C08L33/02 , C08L33/08 , C08L33/14 , A61K47/10 , A61K47/34 , A61K47/40 , A61K47/42 , A61M31/00
Abstract: Residence structures, systems, and related methods are generally provided. Certain embodiments comprise administering (e.g., orally) a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. The residence structure may be, in some cases, a gastric residence structure. In some embodiments, the structures and systems described herein comprise one or more materials configured for high levels of active substances (e.g., a therapeutic agent) loading, high active substance and/or structure stability in acidic environments, mechanical flexibility and strength in an internal orifice (e.g., gastric cavity), easy passage through the GI tract until delivery to at a desired internal orifice (e.g., gastric cavity), and/or rapid dissolution/degradation in a physiological environment (e.g., intestinal environment) and/or in response to a chemical stimulant (e.g., ingestion of a solution that induces rapid dissolution/degradation). In certain embodiments, the structure has a modular design, combining a material configured for controlled release of therapeutic, diagnostic, and/or enhancement agents with a structural material necessary for gastric residence but configured for controlled and/or tunable degradation/dissolution to determine the time at which retention shape integrity is lost and the structure passes out of the gastric cavity. For example, in certain embodiments, the residence structure comprises a first elastic component, a second component configured to release an active substance (e.g., a therapeutic agent), and, optionally, a linker. In some such embodiments, the linker may be configured to degrade such that the residence structure breaks apart and is released from the location internally of the subject after a predetermined amount of time.
-
-
-
-
-
-
-
-
-